No Data
No Data
No Data
No Data
No Data
Algernon NeuroScience and the Centre for Human Drug Research to Present DMT Phase 1 Stroke Clinical Data at the Interdisciplinary Conference on Psychedelic Research June 6 – 8th, 2024
VANCOUVER, British Columbia, April 24, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the "Company" or "AGN Pharma") (CSE:AGN) (FRANKFURT: AGW0) (OTCQB:AGNPF), a Canadian clinical stage pharmaceutical
GlobeNewswireApr 24 19:47
Algernon Pharmaceuticals CEO Christopher J. Moreau to Be Featured on Radius Research's Pitch, Deep Dive and Q&A Webinar on April 16th, 2024
Yahoo FinanceApr 11 19:00
DMT For Stroke Treatment: Algernon Sets Phase 2 Clinical Trial Design
Canadian clinical-stage biotech company Algernon Pharmaceuticals (OTCQB:AGNPF) announced its plans to move forward with an intravenous (IV) formulation of its DMT-based compound AP-188 for the potenti
BenzingaApr 4 04:45
Algernon Pharmaceuticals Strikes Deal to Advance Ifenprodil in Chronic Cough Treatment
Yahoo FinanceMar 28 20:40
Algernon Pharmaceuticals Announces Closing of the Acquisition of Its Chronic Cough Research Program by U.S. Based Seyltx for USD $2M and a 20% Equity Position
VANCOUVER, British Columbia, March 27, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the "Company" or "Algernon") (CSE:AGN) (FRANKFURT: AGW0) (OTCQB:AGNPF), a Canadian clinical stage pharmaceutical
GlobeNewswireMar 28 00:04
Algernon Pharmaceuticals Receives Notice of Intention to Grant From Chinese Patent Office for Repirinast to Treat CKD
Algernon Pharmaceuticals Inc. (AGN.CN), a Canadian clinical stage pharmaceutical development company, on Wednesday announced that it has received a notice of intention to grant from the Chinese Patent
MT NewswiresJan 31 20:49
No Data
No Data